The Rundown Nike Ends Sales Growth Losing Streak, Pfizer Strikes Medicaid Deal with Trump
6 snips
Oct 1, 2025 New insights from the stock market reveal Nike broke its sales growth slump with a surprising 1% revenue increase. Pfizer struck a noteworthy deal to match international drug prices for Medicaid, alongside a hefty investment pledge. Meanwhile, investors are reacting to ongoing market shifts and the FTC has launched a lawsuit against Zillow and Redfin for alleged anti-competitive practices. On a lighter note, Bad Bunny is set to perform at the Super Bowl, highlighting the NFL's controversial minuscule artist payouts.
AI Snips
Chapters
Transcript
Episode notes
Market Momentum Meets Shutdown Risk
- The market closed September strong, marking five straight monthly gains and the best September since 2010.
- A government shutdown introduces uncertainty that pushed investors toward gold, which hit record highs.
Nike Shows Early Turnaround Signs
- Nike reported surprise sales growth, driven by wholesale gains and a 20% jump in running shoe revenue.
- Management still expects profits pressure and doesn't forecast consistent sales growth until 2026.
Pfizer Deal Lowers Price Uncertainty
- Pfizer agreed to match international pricing for Medicaid and new drugs while pledging $70 billion in US investments.
- The deal shields Pfizer from proposed tariffs and gave the stock a significant positive lift.